Magnolol demonstrated dose-dependent enhancement of phagocytosis and inhibition of NO production at the concentration range of 10-40 μM, whereas, in a DSS-induced colitis model, magnolol improved colitis symptoms, including body weight loss and colon length, attenuating pro-inflammatory cytokine levels and histopathological manifestations via modulation of MAPK and NF-κB signaling pathways 485. The gene discussed is NFKB1; the disease is colitis.